Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis
Bedaquiline (BDQ) is a known tuberculosis treatment, but the precise mechanism of cell death is unclear. Here, the authors explore the metabolic profiles of M. tuberculosis upon BDQ treatment and find reliance on glycolysis and synergistic cell death when oxidative phosphorylation is also targeted.
Guardado en:
Autores principales: | Jared S. Mackenzie, Dirk A. Lamprecht, Rukaya Asmal, John H. Adamson, Khushboo Borah, Dany J. V. Beste, Bei Shi Lee, Kevin Pethe, Simon Rousseau, Inna Krieger, James C. Sacchettini, Joel N. Glasgow, Adrie J. C. Steyn |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d680f868a7c742a69cdc3f6e9206d15b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
EMERGENCE OF BEDAQUILINE RESISTANCE AFTER COMPLETION OF BEDAQUILINE-BASED DRUGRESISTANT TB TREATMENT: A CASE STUDY FROM SOUTH AFRICA
por: M. de Vos, et al.
Publicado: (2018) -
Glycolytic reprograming in Salmonella counters NOX2-mediated dissipation of ΔpH
por: Sangeeta Chakraborty, et al.
Publicado: (2020) -
Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming
por: Jia Liu, et al.
Publicado: (2020) -
IN VITRO ACTIVITY OF BEDAQUILINE AGAINST NON-TUBERCULOUS MYCOBACTERIA
por: I. Torres Godino, et al.
Publicado: (2018) -
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Paula J. Gómez-González, et al.
Publicado: (2021)